Table 4.
Summary of meta-analyses for the association between high miR-221/222 expression and survival outcomes in cancer patients.
| Survival Outcome | Studies Included | Test of Association | Test of Heterogeneity | Egger’s p-Value | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-Value | p-Value Q-Test | I2% | |||
| miR-221 | ||||||
| CSS | 3 | 0.75 (0.48–1.17) | 0.205 | 0.148 | 48 | 0.913 |
| CSS/DSS | 4 | 0.95 (052–1.76) | 0.878 | <0.001 | 88 | 0.448 |
| DFS | 6 | 0.79 (0.31–1.98) | 0.614 | <0.001 | 89 | 0.338 |
| RFS | 5 | 1.09 (0.37–3.17) | 0.881 | 0.007 | 71 | 0.443 |
| PFS | 4 | 1.31 (0.65–2.63) | 0.452 | 0.001 | 82 | 0.504 |
| miR-222 | ||||||
| PFS | 7 | 1.67 (1.10–2.51) | 0.015 | 0.001 | 73 | 0.914 |
| DFS | 3 | 2.50 (1.58–3.94) | <0.001 | 0.573 | 0 | 0.053 |
| DFS/RFS | 5 | 2.52 (1.66–3.82) | <0.001 | 0.573 | 0 | 0.143 |
Abbreviations: CSS, cancer-specific survival; DFS, disease-free survival; DSS, disease-specific survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival.